Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Non-Randomized Phase 1/2 Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Patients With Unresectable Locally Advanced or Metastatic Solid Tumors

NCT05706129 is registered in ClinicalTrials.gov with Lumara Bio Oncologics GmbH as lead sponsor.

NCT NCT05706129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05706129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Non-Randomized Phase 1/2 Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Patients With Unresectable Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Lumara Bio Oncologics GmbH
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 14, 2023
Completion date
March 31, 2029
Enrollment
270 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell cancer (ccrcc), colorectal cancer (crc), head and neck cancer (h&n), indeterminate renal mass (idrm), muscle invasive bladder cancer (mibc), pancreatic ductal adenocarcinoma (pdac), squamous non-small cell lung cancer (nsclc), triple negative breast cancer (tnbc), urothelial carcinoma (uc)